CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog developed by ConjuChem with drug affinity complex (DAC) technology for extended half-life. It is not FDA-approved for any indication; ConjuChem discontinued clinical development. It is widely used in research-chemical and telehealth contexts, frequently stacked with ipamorelin.
Growth hormone-releasing hormone (GHRH) analog peptide
CJC-1295 (no DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a tetrasubstituted GHRH 1-29 analog with a half-life of approximately 30 minutes. Unlike the DAC form, it does not bind albumin and is cleared rapidly. It is the standard form combined with ipamorelin in research-chemical and telehealth channels. It is not FDA-approved for any indication, and no standalone clinical trial has evaluated it.
Evidence review
Last reviewed Aug 5, 2026
Next review Sep 5, 2026
Evidence snapshot
CJC-1295 without DAC (Mod GRF 1-29) is a tetrasubstituted GHRH 1-29 analog with D-Ala2, Gln8, Ala15, and Leu27 substitutions that protect against enzymatic degradation without extending half-life beyond approximately 30 minutes.
The no-DAC form lacks the maleimido albumin-binding moiety present in CJC-1295 with DAC, resulting in rapid clearance and a pharmacokinetic profile closer to native GHRH.
CJC-1295 without DAC is the standard form referenced in growth hormone secretagogue stacks, particularly in combination with ipamorelin, across research-chemical vendor catalogs and community protocols.
No published clinical trial has evaluated CJC-1295 without DAC as a standalone compound; the Teichman et al. (2006) study evaluated the DAC form only.
Research record
What the evidence record says
- Evidence grade
- Not Graded
- Regulatory status
- CJC-1295 regulatory status has not been fully reviewed by Peptide Report editorial team. See company profiles and regulatory watch for current status.
- Also known as
- Mod GRF 1-29, Modified GRF 1-29, tetrasubstituted GRF 1-29, CJC-1295 without DAC
Evidence records
Studies, registries, reviews, and regulatory records
Evidence review pending
- Detailed evidence review for CJC-1295 is pending editorial assessment. Current summary reflects available public records.
Records: Pharmacokinetics and Pharmacodynamics of CJC-1295, a Long-Acting GHRH Analog, Certain bulk drug substances for use in compounding may present significant safety risks, Warning Letter: Gram Peptides
Evidence timeline
What changed, and when
Peptide Report last reviewed CJC-1295 on 2026-07-01.
Records: Pharmacokinetics and Pharmacodynamics of CJC-1295, a Long-Acting GHRH Analog
Direct answers
Frequently asked questions
What is CJC-1295?
CJC-1295 is a growth hormone-releasing hormone (ghrh) analog peptide tracked by Peptide Report. See the full profile for current editorial assessment.
Open research questions
What is still unknown
- What is the complete human evidence base for CJC-1295?
- What are the long-term safety considerations for CJC-1295?
Tracked claims
CJC-1295 without DAC (Mod GRF 1-29) is a tetrasubstituted GHRH 1-29 analog with a half-life of approximately 30 minutes, distinct from the DAC form.
Evidence level: Established pharmacology
Sources: Pharmacokinetics and Pharmacodynamics of CJC-1295, a Long-Acting GHRH Analog
How to read this: The four substitutions (D-Ala2, Gln8, Ala15, Leu27) protect against enzymatic degradation but do not extend half-life to the degree seen with the DAC form.
CJC-1295 without DAC is the form commonly combined with ipamorelin in research-chemical and telehealth channels.
Evidence level: Market observation
Sources: Pharmacokinetics and Pharmacodynamics of CJC-1295, a Long-Acting GHRH Analog
How to read this: Vendor catalogs and community discussion consistently reference the no-DAC form in growth hormone secretagogue stacks. The DAC form is rarely used in this context due to its extended half-life and different dosing pattern.
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate CJC-1295 (no DAC) claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Formspree processes this submission for Peptide Report. Privacy notice.
Sources on this page
Each source record is linked to the claim or evidence note it supports.
Pharmacokinetics and Pharmacodynamics of CJC-1295, a Long-Acting GHRH Analog
Teichman et al. (2006) pharmacokinetic study (PMID 16569233) showing that CJC-1295 increased GH and IGF-1 levels in healthy subjects for up to 6 days after a single dose. The primary published human data for CJC-1295.
7 linked pagesOpen original ·
pubmed-cjc1295-pharmacokinetics-2006Certain bulk drug substances for use in compounding may present significant safety risks
FDA compounding-risk page whose withdrawn-nomination table includes GHK-Cu for injectable routes. FDA cites potential immunogenicity from aggregation and peptide-related impurities and states that human safety data are limited. GHK-Cu is not in the page's active Category 2 table.
41 linked pagesOpen original ·
fda-bulk-risk-listWarning Letter: Gram Peptides
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
35 linked pagesOpen original ·
fda-gram-peptides-warning-2026Related compounds
CJC-1295 (with DAC)
CJC-1295 with DAC is a synthetic GHRH analog developed by ConjuChem using drug affinity complex (DAC) technology to bind...
Evidence reviewIpamorelin
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that stimulates GH release via ghrelin receptor...
Evidence reviewMK-677 (Ibutamoren)
MK-677 (ibutamoren) is a non-peptide, orally active growth hormone secretagogue developed by Merck that mimics ghrelin t...
Evidence reviewSermorelin
Sermorelin is a synthetic N-terminal fragment (1-29) of growth hormone-releasing hormone (GHRH) that was formerly FDA-ap...
Evidence reviewStay informed